Decreased prevalence of the Plasmodium falciparum Pfcrt K76T and Pfmdr1 and N86Y mutations post-chloroquine treatment withdrawal in Katete District, Eastern Zambia
Open Access
- 28 July 2021
- journal article
- research article
- Published by Springer Nature in Malaria Journal
- Vol. 20 (1) , 1-8
Abstract
Background: In 2002, Zambia withdrew chloroquine as first-line treatment for Plasmodium falciparum malaria due to increased treatment failure and worldwide spread of chloroquine resistance. The artemisinin combination regimen, artemether–lumefantrine, replaced chloroquine (CQ) as first choice malaria treatment. The present study determined the prevalence of CQ resistance molecular markers in the Pfcrt and Pfmdr1 genes in Eastern Zambia at 9 and 13 years after the removal of drug pressure. Methods: Samples collected from Katete District during the drug therapeutic efficacy assessments conducted in 2012 and 2016 were assayed by polymerase chain reaction (PCR) and restriction fragment length polymorphisms (RFLP) to determine the prevalence of genetic mutations, K76T on the Pfcrt gene and N86Y on the Pfmdr1 gene. A total of 204 P. falciparum-positive DBS samples collected at these two time points were further analysed. Results: Among the samples analysed for Pfcrt K76T and Pfmdr1 N86Y in the present study, 112 (82.4%) P. falciparum-infected samples collected in 2012 were successfully amplified for Pfcrt and 94 (69.1%) for Pfmdr1, while 69 (65.7%) and 72 (68.6%) samples from 2016 were successfully amplified for Pfcrt and Pfmdr1, respectively. In 2012, the prevalence of Pfcrt 76K (sensitive) was 97.3%, 76T (resistant) was 1.8%, and 0.8% had both 76K and 76T codons (mixed). Similarly in 2012, the prevalence of Pfmdr1 86N (sensitive) was 97.9% and 86Y (resistant) was 2.1%. In the 2016 samples, the prevalence of the respective samples was 100% Pfcrt 76K and Pfmdr1 86N. Conclusion: This study shows that there was a complete recovery of chloroquine-sensitive parasites by 2016 in Katete District, Eastern Zambia, 13 years following the withdrawal of CQ in the country. These findings add to the body of evidence for a fitness cost in CQ-resistant P. falciparum in Zambia and elsewhere. Further studies are recommended to monitor resistance countrywide and explore the feasibility of integration of the former best anti-malarial in combination therapy in the future.Keywords
All Related Versions
This publication has 28 references indexed in Scilit:
- The changing burden of malaria and association with vector control interventions in Zambia using district-level surveillance data, 2006–2011Malaria Journal, 2013
- Trends in chloroquine resistance marker, Pfcrt-K76T mutation ten years after chloroquine withdrawal in TanzaniaMalaria Journal, 2013
- Review of the malaria epidemiology and trends in ZambiaAsian Pacific Journal of Tropical Biomedicine, 2013
- Role of Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes on In Vitro Chloroquine Resistance in Isolates of Plasmodium falciparum from ThailandThe American Journal of Tropical Medicine and Hygiene, 2011
- Return of Chloroquine‐Susceptible Falciparum Malaria in Malawi Was a Reexpansion of Diverse Susceptible ParasitesThe Journal of Infectious Diseases, 2010
- In Vivo Selection ofPlasmodium falciparumParasites Carrying the Chloroquine-SusceptiblepfcrtK76 Allele after Treatment with Artemether-Lumefantrine in AfricaThe Journal of Infectious Diseases, 2009
- From chloroquine to artemether-lumefantrine: the process of drug policy change in ZambiaMalaria Journal, 2008
- Return of Chloroquine Antimalarial Efficacy in MalawiNew England Journal of Medicine, 2006
- Reemergence of Chloroquine‐SensitivePlasmodium falciparumMalaria after Cessation of Chloroquine Use in MalawiThe Journal of Infectious Diseases, 2003
- A Molecular Marker for Chloroquine-Resistant Falciparum MalariaNew England Journal of Medicine, 2001